Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes

Endocrine Journal

Volumn 56, Issue 8, 2009, Pages 951-962

  Iwamoto, Kazuya ^a,b   Nasu, Risa ^a,b   Yamamura, Ayuko ^a,b   Kothare, Prajakti A ^a   Mace, Kenneth ^a   Wolka, Anne M ^a   Linnebjerg, Helle ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Sannomiya Plaza Bldg ^*  (Japan)

Author keywords

Asia; Exenatide once weekly; Glycemic control; Japan; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLASE; BIGUANIDE; DRUG ANTIBODY; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; SULFONYLUREA;

ADULT; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; JAPANESE; KINESIOTHERAPY; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TREATMENT DURATION; TREATMENT OUTCOME; VITAL SIGN; VOMITING;

AGED; ALGORITHMS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; MALE; MIDDLE AGED; PEPTIDES; PLACEBOS; VENOMS;

EID: 73549096393     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-147     Document Type: Article

References (30)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053.
2. Yoshiike N, Matsumura Y, Zaman MM, Yamaguchi M (1998) Descriptive epidemiology of body mass index in Japanese adults in a representative sample from the National Nutrition Survey 1990-1994. Int J Obes Relat Metab Disord 22:684-687.
3. Kawamori R (2002) Diabetes trends in Japan. Diabetes Metab Res Rev 18 Suppl 3:S9-S13.
4. Hirose T, Kawamori R (2005) Diabetes in Japan. Curr Diab Rep 5:226-229.
5. Yazaki Y, Kadowaki T (2006) Combating diabetes and obesity in Japan. Nat Med 12:73-74.
6. Pontiroli AE, Calderara A, Pozza G (1994) Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev 10:31-43.
7. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297-303.
8. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012.
9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32:193-203.
10. Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940.
11. Triplitt CL (2007) New technologies and therapies in the management of diabetes. Am J Manag Care 13 Suppl 2:S47-S54.
12. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, de la Pẽna A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie S (2008) Phamacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 48:1389-1399.
13. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG (2009) Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocrine Journal 56:415-424.
14. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493.
15. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; for the DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250.
16. Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS (2005) Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Harm Metab Res 37:627-632.
17. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD (2003) Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377.
18. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635.
19. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100.
20. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091.
21. Zinman B, Hoogwerf BJ, Durán Garcia S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146:477-485.
22. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD (2004) Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20:411-417.
23. Byetta prescribing information. Available at: http://pi.lilly.com/us/ byetta-pi.pdf. Accessed November 1, 2009.
24. International Conference on Harmonisation. ICH topic E5(R1): ethnic factors in the acceptability of foreign clinical data. 1998. Available at: http://www.emea.europa.eu/htms/human/ich/ichefficacy.htm. Accessed November 1, 2009.
25. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT (1995) Postprandial versus preprandial glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333:1237-1241.
26. 1c. IOEZ Study Group. Diabetes Care 23:1236-1241.
27. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354:617-621.
28. Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26:881-885.
29. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687.
30. Riddle MC (2005) Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 34:77-98.